Tumor antigens are the central factors in development of vaccines. They can be delivered to the body along with antigen presenting cells(APCs), immune simulators and immune modulators. Due to availability of new technology, the first gene recognized by T cell, was reported to encode a human tumor antigen and then rapidly molecular identification and characterization of novel tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) including shared antigens, neoantigens, and unique antigens was developed. These antigens serve as a biomarker for identification of the tumor nature and developing novel cancer vaccines. 

For more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000047

https://www.linkedin.com/feed/update/urn:li:activity:6519112999687462912

@cip_usern

Various clinical trials have been conducted to test autologous and allogeneic vaccines for treatment of different types of cancer. Autologous cancer vaccines include unique or rare tumor antigens that develop through mutational events. Allogeneic cancer vaccines, on the other hand, are comprised of intact or modified cancer cells from other patients selected for the presence of shared antigens found on a large percentage of similar tumor types. Their significant advantages are their availability for patients in all stages of the disease and provide the capability to administer multiple vaccinations over a protracted period. Until now, many clinical trials have been conducted but because of great heterogeneity present inter- and intratumorally, few positive results have been attained. 

For more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000059

https://www.linkedin.com/feed/update/urn:li:activity:6519892954117607424

@cip_usern

Personalized medicine is going ahead toward clinical utilization. Due to the recent advances in the “omic” technologies, including genomic studies, the use of individualized approaches has progressed in various diseases including cancer. Individualization has also entered into the field of cancer immunotherapy. Seeking for and selecting the immunogenic neoantigens, which are personalized and unique tumor antigens caused by somatic mutations, is of interest to design specific immunotherapiesincluding vaccines. Recent achievements have been yielded in the clinical trials evaluating synthetic long peptide and poly-neo-epitope RNA vaccines for improvement of disease-free survival in patients at high risk of melanoma recurrence.

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000060

https://www.linkedin.com/feed/update/urn:li:activity:6520341222710616064

@cip_usern
@usern_net

‍ #معرفی_کتاب
#ایمونوتراپی
#USERN
#CIP

🔴عنوان کتاب : 💉💊 Vaccines for Cancer Immunotherapy

♦️مولفین کتاب خانم دکترمهسا کشاورز فتحی و آقای دکتر نیما رضایی ( ویراستار ) سرپرستان و اعضای گروه پژوهشی Cancer Immunology Project هستند که در سال 2016 تاسیس شده است و توانسته عنوان برترین اینترست گروپ #یوسرن را از آن خود کند.کتاب توسط انتشارات #الزیویر در 22 اکتبر 2018 منتشر شده است✍🏻

🔵اeBook ISBN: 9780128140406

🔸تعداد صفحات : 198 📕

💊 @ImmunologyToday💉

🔸توضیح مختصر در مورد کتاب :

❇️واکسن های توموری از جمله روش های ایمونوتراپی فعال محسوب می شوند. پزشکان و محققین در زمینه درمان سرطان بی شک نیازمند منابعی هستند که مبتنی بر جدیدترین شواهد علمی در زمینه واکسن های توموری می باشند.این نوع از واکسن ها به لحاظ درمانی و همینطور به عنوان یکی از زمینه های تحقیقاتی مهم در ایمونوتراپی سرطان بی نهایت حائز اهمیت هستند.در این کتاب مطالب به روش کاملا سازماندهی شده گنجانده شده اند. مولفین کتاب به طور هوشمندانه ای اطلاعاتی در مورد ایمونولوژی سرطان و مطالب کلی در مورد ایمونوتراپی را در بخش های ابتدایی کتاب برای خواننده ارائه نموده اند.. در ادامه در بخش های مختلف با تمرکز بر روی انواع واکسن های توموری آن ها را مبتنی بر آخرین شواهد موجود بررسی نموده اند و در بخش پایانی با نگاهی به آینده چشم انداز این نوع از واکسن ها را ترسیم نموده اند.

💊 @ImmunologyToday💉

♦️بخش های مختلف کتاب 📕

1️⃣ایمونولوژی سرطان
2️⃣رویکردهای ایمونوتراپی در سرطان
3️⃣واکسن ها ، ادجوان ها ، و انواع سیستم دلیوری واکسن ها
4️⃣آنتی ژن های توموری
5️⃣انواع استراتژی در مورد واکسن های توموری اتولوگ و آلوژنیک
6️⃣واکسن های توموری شخصی شده
7️⃣واکسن های های توموری تشکیل شده از کل سلول توموری
8️⃣واکسن های پپتیدی و پروتئینی برای سرطان
9️⃣واکسن های مبتنی بر سلول های ایمنی برای سرطان
🔟واکسن های ژنتیکی برای سرطان
1️⃣1️⃣سرطان های کاندید برای درمان با واکسن های توموری
2️⃣1️⃣موانعی که بر سر راه گسترش واکسن های توموری وجد دارد
3️⃣1️⃣درمان ترکیبی : واکسن های توموری و سایر درمان ها
4️⃣1️⃣نتیجه گیری و چشم انداز آینده در واکسن های سرطانی درمانی

💎 https://www.elsevier.com/books/vaccines-for-cancer-immunotherapy/rezaei/978-0-12-814039-0

@cip_usern
@niima_usern
@usern_net



🌎 به جمع خانواده ی بزرگ ایمونولوژی تودی خوش آمدید🌹
ImmunologyToday.ir
@ImmunologyToday

Cancer vaccines, which are a type of immunotherapeutic agents, have been widely studied for prevention and treatment of tumors. Therapeutic cancer vaccines improve patient's immune response against tumor cells. One of the several types of cancer vaccines is whole tumor cell vaccine. Whole tumor cell vaccines, which consist of allogeneic or autologous tumor cells or tumor cell lines, contain a large variety of characterized and uncharacterized tumor-associated antigensthat could activate antitumor immune reactions. There are several methods for preparation of these vaccines such as tumor cell lysates, tumor-derived exosomes, and irradiated gene-modified tumor cell lines. 

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000072

https://www.linkedin.com/feed/update/urn:li:activity:6521012636237209600

@cip_usern
@usern_net

Tumor antigens are the basis of most cancer vaccine strategies and other types of specific cancer immunotherapy. They are targeted by application of various approaches, and using the peptides containing the epitope(s) of a tumor antigen benefits form an standard and easy method to evoke anticancer immunity. However, some drawbacks are attributed to this simple method, which limit its usage unless optimization is undertaken.

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000084

https://www.linkedin.com/feed/update/urn:li:activity:6521794559817715712

@cip_usern
@usern_net

PID MEETING IN ARMENIA:
Organized by the USERN Ambassador in Armenia

https://bit.ly/2Uy57fl

"Arabkir" Medical Center
Yerevan, Armenia
April 18-19, 2019

2nd J-PROJECT MEETING IN ARMENIA: “Primary immunodeficiency in children”

Free registration for members of all USERN interest groups and USERN offices:
https://forms.gle/TUk2QAgUE14Q19uY8

https://usern.tums.ac.ir/Group/Info/NIIMA

#meeting

@usern_net
@niima_usern

Cancer vaccines have been studied for several years. The focus of these vaccines is treatment of patients with cancer. One of the several types of these vaccines is immune cell vaccine. Dendritic cells (DCs), which are a type of antigen presenting cells, have been widely used for development of immune cell vaccines. These cells can be loaded with different tumor-associated antigens (TAAs), including whole tumor cell lysates, RNA, peptides, and tumor cells. Patients receive these DC-based vaccines, then the DCs present TAAs to immune system and activate antigen specific immune responses against the tumor.

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000096

https://www.linkedin.com/feed/update/urn:li:activity:6523248446734888960

@cip_usern
@usern_net

Genetic-based cancer vaccines, including two major types—DNA vaccines and RNA vaccines—have become an attractive immunotherapeutic approach against cancer due to their various advantages such as simplicity, stability, and safety. The results obtained in clinical trials showed that such DNA and RNA vaccines are required to be ameliorated in antigen expression and delivery methods to make them sufficiently effective in the clinic and provide promising outcomes. Engineering vaccine for modifying antigen presentation and processing pathways is one of the most important aspects that can be managed easily.

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000102

https://www.linkedin.com/feed/update/urn:li:activity:6524306326321917952

@cip_usern
@usern_net

Therapeutic cancer vaccines have been tested in a variety of tumors. Melanoma is one type of cancers that has received the most attention of researchers and clinicians who do research on immunotherapy. Melanoma has the highest mutation rate among various types of cancer and many tumor antigens associated with this malignancy have been identified. However, the most successful results with cancer vaccines have been achieved in patients with prostatecancer. Sipuleucel-T was the first cancer vaccine approved by the US Food and Drug Administration to treat hormone-refractory prostate cancer, which made it a prototype for cancer vaccine therapy. 

For more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000114

https://www.linkedin.com/feed/update/urn:li:activity:6525014846407221248

@cip_usern
@usern_net

Much effort has been dedicated to developing therapeutic cancer vaccines for some decades since the years that identification of various tumor antigens received great attention.
Vaccines showed some positive results in early clinical trials, which made them a promising modality for cancer treatment. However, some negative reports restricted new trials from being conducted to address the efficacy of vaccines, optimization of vaccine dose(s), and combination therapy. At different levels of developing a vaccine, from identifying and validating tumor antigens for specific immunotherapy toward assessing them in clinical trials, some issues should be taken into consideration to overcome the obstacles.

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000126

https://www.linkedin.com/feed/update/urn:li:activity:6525790876004814848

@cip_usern
@usern_net

📘Dr. Nima Rezaei, the Professor of Immunology at Tehran University of Medical Sciences, and the Founding President of USERN, was awarded as the best International Book Editor, in the Joint International Festival of University of Tehran and Tehran University of Medical Sciences.

@niima_usern
@usern_net

The efficacy of cancer vaccines as a monotherapy may be undervalued because of immunosuppression and immune regulatory functions. Combining vaccines with other therapeutics can overcome these barriers and enhance the efficacy of cancer vaccines. Cancer vaccines have been combined with other therapeutics such as chemotherapy, radiation therapy, and small molecule inhibitors, as well as immunotherapy such as cytokines, immune checkpoint inhibitors, and tumor targeted monoclonal antibodies. These combinations have been evaluated in many preclinical and clinical studies. 

Read more:
https://www.sciencedirect.com/science/article/pii/B9780128140390000138

https://www.linkedin.com/feed/update/urn:li:activity:6526850910721708032

@cip_usern
@usern_net

As the field of cancer treatment moves forward, novel treatments are being designed to overcome various malignancies. Therapeutic cancer vaccines had been attractive modalities for many years owing to their capability as an active and specific immunotherapy to direct the immune response toward eliminating tumor cells without severe toxicity for normal cells. Three cancer vaccines were also approved, including Sipuleucel-T licensed by the US Food and Drug Administration for prostate cancer. However, the superiority of vaccines has been questioned in the era of the emergence of novel immunotherapeutics and as a result of some unsuccessful outcomes in phase III trials. Interestingly, despite some unfavorable results, long-term follow-up and administration of vaccines in certain subgroups have significantly improved their efficacy. These experiences became the basis for administering vaccines in certain settings and populations. Moreover, approaches such as neoantigen vaccines have assisted the development of novel vaccines that show promising results. 

For more:
https://www.linkedin.com/feed/update/urn:li:activity:6527483747980312576

https://www.sciencedirect.com/science/article/pii/B978012814039000014X

@cip_usern
@usern_net

Day of Immunology, 29 April
DOI 2019

"Cancer Checkpoint Blockade"

https://www.dayofimmunology.org

🆔@niima_usern
🆔@usern_net

Happy Professor Day🌹

@niima_usern

The Immune System for Public: Interview with the National TV3

سیستم ایمنی بدن و بیماریهای آن به زبان ساده برای عموم مردم در مصاحبه با شبکه سه سیما

@niima_usern
@cip_usern
@usern_net

🎉بیش از پانصد مقاله با افیلیشن یوسرن در اسکوپوس به ثبت رسید.

@usern_net

Physiology and Pathology of Immunology

Edited by Nima Rezaei

The "Physiology and Pathology of Immunology" book covers a spectrum of high-impact knowledge on the complex interplay between the environment, genes, and immunity that culminates in a generation of notorious processes of immune-related disorders. From evolution of regulatory T-cell function, gigantic cytokine networks within the human body to host-pathogen interactions of Chagas disease and Parkinson's disease, the Physiology and Pathology of Immunology goes further to decipher new codes from the immunity enigma, making it essential for experienced and new learners who wish to join the galaxy of modern immunology.

To free download the chapters:
https://www.intechopen.com/books/physiology-and-pathology-of-immunology

#book

@niima_usern
@cip_usern
@usern_net

عده ای از محققین ایرانی با راه اندازی وبسایتی به بررسی مطالعات مهم و چالش برانگیز پزشکی می‌پردازند و آنها را از نظر سوگیری های مهم ارزیابی می کنند که نتایج آن در وبسایت قابل مشاهده است.
ظاهرا بعد از افزایش تعداد همکاران در این وبسایت، تعداد مقالات مورد بررسی نیز افزایش می باید. بر اساس اطلاعات ذکر شده، این پایگاه، اولین وبسایتی است که روش شناسی مطالعات را می سنجد

unravelmedicine.com

🌐EAACI Junior Membership for FREE!

European Academy of Allergy and Clinical Immunology

🔹EAACI Junior Membership shall be available to all those who are aged 35 years or less at the time of renewal of their subnoscription.
🔹The benefits of Junior Membership shall be determined by the Executive Committee and publicised at Congresses, Joint Symposia, and other EAACI events, as well as on forms for enrolment and membership renewal.

https://www.eaaci.org/40-organisation/bylaws/2378-junior-membership

https://registration.eaaci.org/EAACIMemberRegistration.aspx

#Membership

@niima_usern
@cip_usern